The Prevalence of Cardiovascular Risk Factors in Patients More Than 10 Years Following Successful Renal Transplant.

Helse Stavanger HF1 site in 1 country60 target enrollmentNovember 2012

ConditionsRenal Transplant

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Renal Transplant
Sponsor: Helse Stavanger HF
Enrollment: 60
Locations: 1
Primary Endpoint: Fibroblast growth factor 23 (FGF23)
Status: Completed
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Mineral metabolism disturbances occur early during the course of chronic kidney disease and eventually affect most patients. For how long such disturbances persist after a successful renal transplantation is mainly unknown. This study will investigate the prevalence of such disturbances in patients more than 10 years following a successful renal transplantation. The patients will be recruited from an existing registry in Norway.

Registry

clinicaltrials.gov

Start Date

November 2012

End Date

November 2013

Last Updated

11 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Helse Stavanger HF

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Registered in the Norwegian Renal Registry
•Documented elevated iPTH at Tx and 10 weeks post-tx
•Well functioning transplant 10 years following tx
•Signed informed consent

Exclusion Criteria

•Lack of ability to comply with the protocol
•Refused written informed consent

Outcomes

Primary Outcomes

Fibroblast growth factor 23 (FGF23)

Time Frame: More than 10 years after successful renal transplantation

To evaluate the long-term effect of a successful renal transplant on this biomarker.

Secondary Outcomes

Klotho(More than 10 years after successful renal transplantation)
Intact parathyroid hormone (iPTH)(More than 10 years after successful renal transplantation)
Neutrophil gelatinase-associated lipocalin (NGAL)(More than 10 years after successful renal transplantation)